<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01968941</url>
  </required_header>
  <id_info>
    <org_study_id>OCOG-2013-LUSTRE</org_study_id>
    <nct_id>NCT01968941</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiotherapy Versus Conventional Radiotherapy in Medically-Inoperable Non-Small Lung Cancer Patients</brief_title>
  <acronym>LUSTRE</acronym>
  <official_title>A Randomized Trial of Medically-Inoperable Stage 1 Non-small Cell Lung Cancer Patients Comparing Stereotactic Body Radiotherapy Versus Conventional Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ontario Clinical Oncology Group (OCOG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Cancer Society Research Institute (CCSRI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ontario Clinical Oncology Group (OCOG)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-centre randomized controlled open-label trial in medically inoperable patients with
      biopsy-proven early stage non-small cell lung cancer (NSCLC). Eligible and consenting
      patients will be randomly allocated to receive stereotactic body radiotherapy (SBRT) or
      conventional radiotherapy (CRT) in a 2:1 ratio. Radiotherapy will be administered as soon as
      possible following randomization and subjects will be followed for 5 years post-randomization
      for cancer recurrence, toxicity and survival. The primary outcome is local control (LC). The
      trial will be conducted at 16-20 clinical centres throughout Canada.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2014</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local Control</measure>
    <time_frame>5 years</time_frame>
    <description>Local control is the absence of local recurrence during the study period. This is the time from randomization to primary tumour failure or marginal failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall Survival is defined as the time from randomization to death from any cause. Alive subjects will be censored on the date of last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Disease-Free Survival is defined as the time from randomization to the earliest recurrence of disease or to death attributed to lung cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Event-Free Survival is defined as the time from randomization to the earliest documented recurrent disease or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Cancer-Specific Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Lung Cancer-Specific Survival is defined as the time from randomization to death attributable to lung cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation Treatment-Related Death</measure>
    <time_frame>1 to 12 months</time_frame>
    <description>Radiation Treatment-Related Death is defined as death occurring between 1 to 12 months following treatment, and caused directly by radiation toxicity attributed to either catastrophic hemorrhage or to severe radiation pneumonitis leading to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>5 years</time_frame>
    <description>Acute Toxicity will be assessed at 3 months post-randomization and includes fatigue, dyspnea and esophagitis. Late toxicity will be assessed beyond 3 months and up to 5 years and includes radiation pneumonitis, chest wall pain and rib fracture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>2 years</time_frame>
    <description>Impact on quality of life will be assessed with the European Organization for Research in Treatment of Cancer and the Lung Cancer-specific Module 13 questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-Utility</measure>
    <time_frame>3 years</time_frame>
    <description>Cost-Utility will be assessed using the European Quality of Life questionnaire in conjunction with the overall survival results</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">324</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Stereotactic Body Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stereotactic Body Radiotherapy (SBRT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional Radiotherapy (CRT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiotherapy (SBRT)</intervention_name>
    <arm_group_label>Stereotactic Body Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventional Radiotherapy (CRT)</intervention_name>
    <arm_group_label>Conventional Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. T1/T2a N0 M0 NSCLC, either by: (a) histological confirmation (squamous cell,
             adenocarcinoma, large cell carcinoma, or not specified) and CT thorax and/or PET-CT
             evidence, or (b) a suspicious growing nodule on serial CT imaging, with malignant PET
             Fluorodeoxyglucose (FDG) avidity, for which a biopsy would be extremely risky.

          2. Deemed medically inoperable (as reviewed by a thoracic surgeon and defined as
             surgically resectable but, because of underlying physiological medical problems [e.g.
             chronic obstructive pulmonary disease (COPD), heart disease], surgery is
             contraindicated) or Radiotherapy is preferred by the patient due to high operable
             risk.

        Exclusion Criteria:

          1. Less than 18 years of age.

          2. Eastern Cooperative Oncology Group (ECOG) performance status 3 or higher.

          3. Prior invasive malignancy within the past 3 years (excluding non-melanomatous skin
             cancer).

          4. History of ataxia telangiectasia.

          5. Previous radiotherapy (RT) in the vicinity of the tumour, such that significant
             overlap could occur.

          6. Previous pneumonectomy with Stage I lung cancer in the remaining lung.

          7. Diagnosis of idiopathic pulmonary fibrosis and/or interstitial lung disease.

          8. Planned for other anticancer therapy (chemotherapy, biological targeted therapy).

          9. Female, who is currently pregnant or lactating.

         10. Geographic inaccessibility for follow-up.

         11. Unable to provide informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anand Swaminath</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ontario Clinical Oncology Group (OCOG)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tim Whelan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ontario Clinical Oncology Group (OCOG)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathryn Cline</last_name>
    <phone>905-527-2299</phone>
    <phone_ext>42650</phone_ext>
    <email>clinek@mcmaster.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Nason</last_name>
    <phone>905-527-2299</phone>
    <phone_ext>42622</phone_ext>
    <email>nasons@mcmaster.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Harold Lau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Zsolt Gabos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BCCA Vancouver Island Cancer Centre</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Cancer Care Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Naseer Ahmed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Horizon Health Network</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Amanda Caissie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juravinski Hospital and Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anand Swaminath</last_name>
    </contact>
    <investigator>
      <last_name>Anand Swaminath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario at the Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Timothy Owen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program at London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexander Louie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Niagara Health System-Walker Family Cancer Centre</name>
      <address>
        <city>St. Catharines</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Theos Tsakiridis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Sciences Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kevin Ramchandar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Windsor Regional Cancer Centre</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Khalid Hirmiz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charles LeMoyne Hospital</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Selma Mehiri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUM Hospital Notre Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marie-Pierre Campeau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexis Bujold</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal General Hospital McGill</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bassam Abdulkarim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nelson Leong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vijay Kundapur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2013</study_first_submitted>
  <study_first_submitted_qc>October 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2013</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stereotactic body radiotherapy</keyword>
  <keyword>conventional radiotherapy</keyword>
  <keyword>inoperable patients</keyword>
  <keyword>local control</keyword>
  <keyword>cancer recurrence</keyword>
  <keyword>toxicity</keyword>
  <keyword>survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

